United Kingdom

People: Collegium Pharmaceutical Inc (COLL.OQ)

COLL.OQ on NASDAQ Stock Exchange Global Select Market

17 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Brannelly, Paul 

Mr. Paul Brannelly, CPA is the Chief Financial Officer, Executive Vice President of Collegium Pharmaceutical Inc. since February 2015. Prior to joining us, Mr. Brannelly served as Senior Vice President, Finance and Administration, and Treasurer of Karyopharm Therapeutics Inc., a biopharmaceutical company, from June 2013 to August 2014. From August 2014 to November 2014, Mr. Brannelly served as a consultant to Karyopharm. Prior to joining Karyopharm, Mr. Brannelly served as Vice President, Finance, Treasurer and Secretary at Verastem, Inc. from August 2010 to May 2013. From January 2010 to September 2011, Mr. Brannelly held the position of Chief Financial Officer at the Longwood Fund, a venture capital firm aimed at investing in, managing and building healthcare companies, where he set up the financial and operational infrastructure following the closing of its first fund and eventually served as Chief Financial Officer of its two startup companies, Verastem and OvaScience, Inc. From November 2005 to September 2009, he served as Vice President, Finance at Sirtris Pharmaceuticals, Inc., a biopharmaceutical company which GlaxoSmithKline plc purchased for $720 million in 2008. Mr. Brannelly started his biopharmaceutical career at Dyax Corporation from September 1999 to May 2002, and subsequently moved on to positions of increasing responsibility at CombinatoRx Inc. from May 2002 to November 2005, including as Vice President, Finance and Treasurer, where he led the initial public offering process. Mr. Brannelly graduated from the University of Massachusetts at Amherst with a B.B.A. in Accounting in 1995.

Basic Compensation

Total Annual Compensation, USD 387,692
Restricted Stock Award, USD 608,750
Long-Term Incentive Plans, USD --
All Other, USD 979,062
Fiscal Year Total, USD 1,975,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Heffernan


Joseph Ciaffoni


Paul Brannelly


Alison Fleming


Shirley Kuhlmann


Scott Dreyer

As Of  31 Dec 2018